- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class: Antibody
Comment: The peptide sequences for the heavy and light chains that form this antibody are annotated in its IMGT/mAb-DB record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: vedolizumab
1. Ponath PD, Ringler DJ, ST, Newman W, Saldanha J, Bendig MM. (2006)
Humanized immunoglobulin reactive with α4β7 integrin.
Patent number: US7147851 B1. Assignee: Millennium Pharmaceuticals, Inc.. Priority date: 15/08/1996. Publication date: 12/12/2006.
2. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. (2009)
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
J. Pharmacol. Exp. Ther., 330 (3): 864-75. [PMID:19509315]